Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises MinIO on $103 Million Series B
On January 26, 2022, MinIO Inc., creators of the MinIO multi-cloud object storage suite, announced it raised $103 million in Series B funding at a $1 billion valuation. The investment was led by Intel Capital with participation from new investor SoftBank Vision Fund 2, and existing investors Dell Technologies Capital, General Catalyst, and Nexus Venture Partners. The financing brings MinIO’s total funding raised to $126 million. Wilson Sonsini Goodrich & Rosati represented MinIO in the transaction.
Client Highlights
Wilson Sonsini Advises Sonder on Close of Business Combination with Gores Metropoulos II
On January 18, 2022, Sonder Holdings Inc., a leading next-generation hospitality company that is redefining the guest experience through technology and design, announced that it completed its previously announced business combination with Gores Metropoulos II, Inc., a special purpose acquisition company sponsored by affiliates of The Gores Group, LLC, and Metropoulos & Co. The business combination was approved at a special meeting of Gores Metropoulos II stockholders on January 14, 2022. The combined company, operating as Sonder Holdings Inc., commenced trading its common stock and publicly traded warrants on the Nasdaq Global Select Market on January 19, 2022, under the ticker symbols “SOND” and “SONDW,” respectively.
Client Highlights
Wilson Sonsini Advises SR One on Corporate, IP Matters Related to Simcha Therapeutics’ $40 Million Series B Financing
On January 27, 2022, Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40 million Series B financing. The round was led by SR One Capital Management and joined by other new investors including BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital. Wilson Sonsini Goodrich & Rosati advised SR One on corporate and IP matters related to the transaction.
Client Highlights
Wilson Sonsini Represents BitFuFu in Business Combination with Arisz Acquisition
On January 25, 2022, FinFront Holding Company (BitFuFu), a fast-growing digital asset mining service and world-leading cloud-mining service provider, and Arisz Acquisition Corp. (ARIZ) announced a business combination through which BitFuFu will become a publicly listed company on NASDAQ under the anticipated ticker symbol "FUFU." Wilson Sonsini Goodrich & Rosati represented BitFuFu in the transaction.
Client Highlights
Wilson Sonsini Pro Bono Victory in Medicare Class Action Affirmed, Stands to Protect Appeal Rights for Vulnerable Medicare Patients Nationwide
Previously, in March 2020, Wilson Sonsini, along with co-counsel Center for Medicare Advocacy (CMA) and Justice in Aging, obtained a trial victory at the district court level on behalf of a nationwide class of Medicare beneficiaries to appeal adverse classifications that affected their right to Medicare coverage for often critical care. On January 25, 2022, following an appeal and challenge of the ruling by the defendant, a panel of the U.S. Court of Appeals for the Second Circuit issued an opinion, stating “we find no merit in these challenges. We therefore AFFIRM.”
Client Highlights
Wilson Sonsini Advises Metagenomi on Patent Matters Related to $175 Million Series B
On January 25, 2022, Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced the completion of an up-sized and oversubscribed $175 million Series B financing. This brings the total amount of funding for the company to $300 million. Proceeds from the financing will be used to advance Metagenomi’s lead in vivo and ex vivo gene editing therapeutic programs through preclinical development and into the clinic. This will include expansion of its manufacturing, automation and AI infrastructure, and further development of the company’s differentiated toolbox of next-generation gene editing systems. Wilson Sonsini Goodrich & Rosati advised Metagenomi on patent matters related to the transaction.
The Life Sciences Report - January 2022
This latest issue features articles on Foresight Diagnostics co-founder and CEO Jake Chabon, recent pharmaceutical antitrust developments and expectations for 2022, life sciences venture financings in which clients participated across 2H 2020 and 1H 2021, and the firm’s newly launched Salt Lake City office. It also includes a discussion of the Genus v. FDA decision, the FDA’s regulatory framework for innovator drug products and public disclosures, and a summary of select recent life sciences client highlights.